<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>178</id><JournalTitle>A STUDY ON EFFICACY OF TAMSULOSIN IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA: A PROSPECTIVE</JournalTitle><Abstract>Tamsulosin hydrochloride can significantly improve benign prostatic hyperplasia (BPH) symptoms after the
first dose and achieve long-term efficacy in European and American populations; however, the corresponding studies from
India are rarely seen. The purpose of this study was to evaluate the long-term efficacy and safety of Tamsulosin
hydrochloride 0.4 mg once daily in patients with BPH in Kerala, India. Objective: To evaluate the efficacy of Tamsulosin in
the management of benign prostatic hyperplasia, who was treated for 1 month. Materials and method: Of the 96 patients from
the urology department who participated in this investigation, 83 patients were evaluable. Tamsulosin 0.4 mg/day was
administered orally for a 1month period. The primary efficacy parameters were improvement in the total, obstructive and
irritative International Prostate Symptom Score (IPSS), measured at baseline and at 1 month, and in the maximal urinary flow
rate (Qmax) measured at baseline and at 1 month. The secondary efficacy parameters were a decrease of ?30% in IPSS and
an increase in Qmax of ?30% from baseline. Changes in parameters between baseline and at 1 month were assessed using
Student’s paired t-test. Results: Statistically significant, gradual improvements in all efficacy parameters were observed over
the 1month period. Tamsulosin 0.4 mg/day resulted in a mean reduction in total IPSS (p &lt; 0.001) and a mean increase of
4.56 mL/sec in Qmax, Qavg and Voided volume at 1 month (p &lt; 0.001). Conclusion: Our study suggests that Tamsulosin
0.4mg is effective for the treatment of Benign Prostatic Hyperplasia in elderly patients. The severity of symptoms was
assessed by using IPSS and we concluded that, after 1 month of therapy, symptoms are reduced. Statistically significant
gradual improvement in efficacy parameters was observed over 1 month period</Abstract><Email>sunuasna555@gmail.com</Email><articletype>Research</articletype><volume>12</volume><issue>2</issue><year>2022</year><keyword>Benign Prostatic Hyperplasia,Tamsulosin,Adrenoceptor Antagonists,Receptor Subtype</keyword><AUTHORS>Kadeeja asna,Leslin Mary Baby,Athira Ramakrishnan,Muhammed Asif,V. Karthikeyan,Pravin Dass</AUTHORS><afflication>Department of Pharmacy Practice Grace College of Pharmacy, Palakkad, Kerala, India,Department of Pharmacy Practice Grace College of Pharmacy, Palakkad, Kerala, India,Department of Pharmacy Practice Grace College of Pharmacy, Palakkad, Kerala, India,Department of Pharmacy Practice Grace College of Pharmacy, Palakkad, Kerala, India,Department of Pharmacy Practice Grace College of Pharmacy, Palakkad, Kerala, India,Department of Urology, Karuna Medical College and Hospital, Palakkad, Kerala, India</afflication></Article></Articles>